287 related articles for article (PubMed ID: 22647972)
1. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
Custodio A; Feliu J
Crit Rev Oncol Hematol; 2013 Jan; 85(1):45-81. PubMed ID: 22647972
[TBL] [Abstract][Full Text] [Related]
2. Development of molecular biomarkers in individualized treatment of colorectal cancer.
De Mattos-Arruda L; Dienstmann R; Tabernero J
Clin Colorectal Cancer; 2011 Dec; 10(4):279-89. PubMed ID: 21729679
[TBL] [Abstract][Full Text] [Related]
3. Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.
Sartore-Bianchi A; Bencardino K; Di Nicolantonio F; Pozzi F; Funaioli C; Gambi V; Arena S; Martini M; Lamba S; Cassingena A; Schiavo R; Bardelli A; Siena S
Target Oncol; 2010 Mar; 5(1):19-28. PubMed ID: 20383783
[TBL] [Abstract][Full Text] [Related]
4. Predictive molecular classifiers in colorectal cancer.
Bohanes P; LaBonte MJ; Winder T; Lenz HJ
Semin Oncol; 2011 Aug; 38(4):576-87. PubMed ID: 21810517
[TBL] [Abstract][Full Text] [Related]
5. Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma.
Dempke WC; Heinemann V
Anticancer Res; 2010 Nov; 30(11):4673-7. PubMed ID: 21115922
[TBL] [Abstract][Full Text] [Related]
6. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; Di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A; Trusolino L
Cancer Discov; 2011 Nov; 1(6):508-23. PubMed ID: 22586653
[TBL] [Abstract][Full Text] [Related]
7. Molecular predictors of response to chemotherapy in colorectal cancer.
Dienstmann R; Vilar E; Tabernero J
Cancer J; 2011; 17(2):114-26. PubMed ID: 21427555
[TBL] [Abstract][Full Text] [Related]
8. The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer.
Yarom N; Jonker DJ
Discov Med; 2011 Feb; 11(57):95-105. PubMed ID: 21356164
[TBL] [Abstract][Full Text] [Related]
9. Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer.
Asghar U; Hawkes E; Cunningham D
Clin Colorectal Cancer; 2010 Dec; 9(5):274-81. PubMed ID: 21208841
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.
Banck MS; Grothey A
Clin Cancer Res; 2009 Dec; 15(24):7492-7501. PubMed ID: 20008849
[TBL] [Abstract][Full Text] [Related]
11. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.
Bouché O; Beretta GD; Alfonso PG; Geissler M
Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S1-10. PubMed ID: 20189053
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer.
Okada Y; Miyamoto H; Goji T; Takayama T
Digestion; 2014; 89(1):18-23. PubMed ID: 24458108
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
Modjtahedi H; Essapen S
Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
[TBL] [Abstract][Full Text] [Related]
14. EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.
Berg M; Soreide K
Discov Med; 2012 Sep; 14(76):207-14. PubMed ID: 23021375
[TBL] [Abstract][Full Text] [Related]
15. Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.
Troiani T; Zappavigna S; Martinelli E; Addeo SR; Stiuso P; Ciardiello F; Caraglia M
Expert Opin Biol Ther; 2013 Feb; 13(2):241-55. PubMed ID: 23281932
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic mutations as predictive factors in colorectal cancer.
Lièvre A; Blons H; Laurent-Puig P
Oncogene; 2010 May; 29(21):3033-43. PubMed ID: 20383189
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action.
Heinemann V; Douillard JY; Ducreux M; Peeters M
Cancer Treat Rev; 2013 Oct; 39(6):592-601. PubMed ID: 23375249
[TBL] [Abstract][Full Text] [Related]
18. [Perspective of personalized (precise) cancer therapy based on predictive biomarkers].
Osera S; Yoshino T
Nihon Rinsho; 2014 Jan; 72(1):29-34. PubMed ID: 24597345
[TBL] [Abstract][Full Text] [Related]
19. Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer.
Yang J; Li S; Wang B; Wu Y; Chen Z; Lv M; Lin Y; Yang J
Tumour Biol; 2016 Sep; 37(9):11645-11655. PubMed ID: 27422777
[TBL] [Abstract][Full Text] [Related]
20. EGFR-targeted therapy in colorectal cancer: does immunohistochemistry deserve a role in predicting the response to cetuximab?
Valentini AM; Pirrelli M; Caruso ML
Curr Opin Mol Ther; 2008 Apr; 10(2):124-31. PubMed ID: 18386224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
